Executing clinical proteomic studies using mass spectrometry

Abstract

SummaryBiomarkers are tools of personalized medicine and potentially valuable end points for clinical studies. They can be used to measure a patient's risk to certain disease and the severity of the disease, and to predict and/or measure the patient's therapeutic response to treatment. Mass spectrometry (MS) enables simultaneous detection and quantification of most proteins, and therefore has become an attractive method for biomarker discovery in the recent years. It can be used to detect changes in cellular functions and metabolism in a more comprehensive way than the traditional immunoassays. In this presentation, the techniques used in sample preparation and MS will be demonstrated in a practical way. The presentation will cover methods used through the different phases of clinical proteomic studies from planning to discovery and validation of discovered biomarkers.